Li Chen, Ph.D., Head of Research, CSO, Roche R&D Center (China) Limited Dr. Chen is Head of Research and CSO at Roche R&D center in China and is responsible for the drug discovery research strategy and operation in China. He is also a member of Roche Global Chemistry team and Board of Directors of Roche R&D Center (China) Ltd. Li joined Roche Nutley Research Center (USA) in 1992 after his Ph.D in Chemistry from Iowa State University and had several managerial positions in PR&D Nutley. He is co-inventors of two Roche drugs currently in Phase II trail. Li is a member of BOD of Sino-American Pharmaceutical Association (SAPA) and Scientific Committee of the Chemogenomic Lab at Peking University.
	Eric Morfin, PMP, Director, Project Management Office, Novartis Vaccines and Diagnostics Mr. Morfin, has been a project manager since 1987. A sought after speaker on the subject of Project Management, Portfolio Management, and Critical Thinking Skills at North American and European symposiums and conferences, Mr. Morfin has been published many times in PM Magazines and Pharmaceutical publications. Currently co-author of several Project Management in Pharmaceuticals books, Mr. Morfin is an active member of several professional societies and has developed several unique seminars on Project Management in Drug Development such as “Project Management in Discovery and Preclinical” and “Project Management for Global Clinical Trials”. He is the chair of the PMI Pharmaceutical SIG and Vice Chair of the New Product Development and Metrics SIGs. He has consulted with clients in a variety of industry settings throughout North America, Europe, and Asia. He has worked with Genentech, Merck Frost, GlaxoSmithKline, Aventis, Novartis, Bristol Myers-Squibb, Biogen Idec, Millenium Pharmaceuticals, and AstraZeneca to name only a few.
	Mao Mao, M.D., Ph.D., Associate Director/China Project Liaison, Oncology Clinical Research, Merck Research Laboratories Dr. Mao is Associate Director of Oncology Clinical Research for Merck Research Laboratories, Merck & Co., Inc. Currently he coordinates extensive collaborations with Chinese institutions to promote personalized cancer therapy in China. As one of the founding members of the National Human Genome Center at Shanghai, he established the first high-throughput DNA sequencing facility and pioneered genome research in China.
	Jingsong Wang, M.D., Associate Director Translational Medicine, Wyeth Research Labs Dr. Wang is an Associate Director, Translational Medicine, Wyeth Research. Prior to joining Wyeth, Dr. Wang was at Brigham and Women’s Hospital and Harvard Medical School where he was Attending Rheumatologist. Dr. Wang had extensive experience in translational research in inflammation and autoimmune diseases spanning more than 10 years prior to moving to industry. Dr. Wang is Board Certified in Rheumatology, a diplomate of American Board of Internal Medicine. Dr. Wang’s academic appointments includes a visiting professorship in Medicine at Xuzhou Medical College in China, Research Grant Review Committee on Immunology and National Natural Science Foundation of China (NSFC) and has served as a member of the expert panel for the Biotechnology Industry Organization (BIO) Congressional Staff Briefing on Biotechnology and Autoimmune Diseases, Capitol Hill, Washington DC.
	Jonathan Wang, Ph.D., M.B.A., General Manager (Greater China) Burrill & Company As the General Manager (Greater China) at Burrill & Company, Dr. Wang leads the firm’s Greater China-related business. Prior to Burrill, Dr. Wang worked for WI Harper Group and Walden International, both ranked among the top ten global venture capital firms operating in China. At WI Harper, operating in the U.S., Mainland China, Taiwan and Singapore, Dr. Wang was Managing Director, overseeing the firm’s life sciences activities worldwide and leading the company’s Merchant Banking Group. He was a thought leader in the cross-Pacific life sciences outsourcing and partnering, and co-founded Bridge Pharmaceuticals, a pioneering cross-Pacific pharmaceutical R&D services company. He managed WI Harper’s life sciences investments, including Bridge Pharmaceuticals, StemCyte, AVIVA Biosciences and U-Systems. Prior to WI Harper, Dr. Wang began his venture capital career at Walden International, operating in twelve countries in Asia from its headquarters in the U.S. He co-managed Walden’s life sciences investments and helped monitor its portfolio companies, including Asia Renal Care, LXN, NextCare Hospitals and Elitra Pharmaceuticals. While at Walden, he co-founded Eureka! Pharmaceuticals, developed significant intellectual property in the area of modernized Traditional Chinese Medicine (TCM), and was an early proponent of the use of the Internet as a development and marketing tool for medical technology companies. Dr. Wang holds a Ph.D. in Molecular Neurobiology from Columbia University. He obtained his scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate, and was awarded Howard Hughes Medical Institute (HHMI) Research Fellowship. He also holds an M.B.A. from Stanford University.
	Jeffrey L. Winkelhake, Ph.D., Vice President, International Operations, Sino Biopharmaceuticals, Ltd., Beijing/ Hong Kong, PRC Dr. Winkelhake is the assistant to the President of the company. He joined the group in May 2005. He is principally responsible for the group’s international operations, business development, and management. He has over 30 years of experience in the American medical and pharmaceutical business. After receiving his Ph.D. from the University of Illinois and post-doctoral training at The Salk Institute, Dr. Winkelhake went through the ranks to Professor, Medical Microbiology & Immunology at The Medical College of Wisconsin. In 1983 he joined Cetus, Corp. (now Chiron), in San Francisco, directing preclinical development for one of the first biotechnology companies in the USA. In the 1990’s he worked in executive management with Cytel Corp., and Anergen, Inc., before becoming President and CEO of Analytica Therapeutics, Inc. in San Francisco -a US-Australian joint venture- in 2000.
	Tony Xiaogang AN, Chief of Biopharmaceutical Division, Investment Promotion Center, Tianjin Economic Development Bureau Mr. Tony Xiaogang AN is the Chief of Biopharmaceutical Division of TEDA Investment Promotion Center. He has been working in TEDA for five years and assisted several foreign investors to set up local businesses including Kennametal, Synzme, Wuxi Phamatech and TEVA’s acquisition of a local company. He received his Bachelor of Engineering at Tianjin University on 1998 and a MBA at Nankai University.
	Hongjun Yang, Ph.D., Vice President, Tianjin Biochip Company Hongjun Yang, Ph.D., Vice president, has recently joined TBC. Prior to this post, he was vice president and executive director at Shanghai Biochip Company where he successfully built the partnership with Affymetrix, Bio-Rad, Merck, etc. Before returning to China, Dr. Yang worked in the USA for 18 years at the executive management level for a number of biotech companies such as IGEN, Genometrix, Nanogen, Gene Logic, etc.
	Thomas Hooker Bliss, Jr., Director of Licensing, Amgen Inc. Mr. Bliss joined Amgen in 2004 and is currently the Director for International Licensing. In this role, he is responsible for International Licensing, Licensing Operations oversight, and the China/India R&D Initiative coordination and communication. Prior to joining Amgen, Mr. Bliss worked within Licensing and Acquisition Analysis at Johnson & Johnson and later directed the licensing and acquisition activity at Baxter BioScience BioPharmaceuticals business unit. Additionally, for nearly half his career, Mr. Bliss executed financing and provided merger and acquisition advisory services with investment banks Lehman Brothers, DLJ and SG Cowen. He brings a varied perspective to partnering transactions having served as an agent, advisor, and principal across various types of licensing and acquisition transaction structures. Mr. Bliss received a BA in English and Asian Studies (Mandarin Chinese) from Dartmouth College and an MBA in Finance and Marketing from The Wharton School, University of Pennsylvania.
	Canwen Jiang, M.D., Ph.D., Genzyme Science China Principal Representative, Scientific Director, Applied Discovery Research, Genzyme Corporation After receiving medical and research training in China, UK, and US, Dr. Jiang joined Genzyme in 1994. He is currently Scientific Director, Applied Discovery, and Genzyme Science China Principal Representative. Dr. Jiang has been playing a leading role in Genzyme’s R&D activities in China.
	Angela Wong, Ph.D., Vice President, Service Biology, WuXi PharmaTech Dr. Wong is the Vice President of Service Biology at WuXi PharmaTech. Prior to joining the company, Dr. Wong spent 20 years in pharmaceutical research at SmithKline, Pharmacopeia, and Vitae Pharmaceuticals. She has experience in multiple therapeutic areas including inflammation, cancer, hypertension, and osteoporosis. Dr. Wong received her Bachelor of Science Degree in Biochemistry from Chinese University of Hong Kong and Ph.D. in Pharmacology from Baylor College of Medicine in Texas.
	Suresh Poosala D.V.M., M.S. Ph.D., Chief of Comparative Medicine and Animal Program Director, NIA/NIH Dr. Poosala is a veterinary pathologist from Iowa State University and lab animal residency trained at University of Maryland. He has been serving in the roles of Lab Animal Program Director and Chief of Comparative Medicine at NIA along with several other additional responsibilities. He is an active participant in meetings regarding animal welfare, regulations and is an ad hoc site visitor with AAALAC. He is now actively involved in the conceptualizing, design and commissioning of a state-of-the-art brand new vivarium. During his association with Pathology and Lab animal facility management for the last 12 years, he has gained immense experience in this emerging field.
	John B. Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc. Dr. Stoudemire received his Ph.D. in Microbiology from the University of Miami and completed a postdoctoral fellowship at the Cardiovascular Research Institute at the University of California San Francisco. Dr. Stoudemire joined Ascenta in 2005 as Vice President of Preclinical Development. He has held senior positions at Chugai-Roche Pharmaceuticals, Cytel Corporation, Genetics Institute, and Xoma. In these positions, Dr. Stoudemire was responsible for the preclinical evaluation of a broad range of small molecules and biologics including cytokines, growth factors, hematopoietic factors, enzymes, carbohydrates, and antibodies. Dr. Stoudemire is a founding member of the Executive Committee of BioSafe. In his position with Ascenta, he has evaluated preclinical development capabilities in China, and he has established a preclinical development group in Shanghai.
	Glenn Rice, Ph.D., CEO, Bridge Pharmaceuticals, Inc. Dr. Rice is founder and CEO and President of Bridge Pharmaceuticals, Inc. Bridge is the leading preclinical contractor of Asian FDA compliant drug development services for the U.S. and EU markets. Previously (2002-2004), Dr. Rice headed life sciences at SRI International, was Board Director and Vice President of Research at ILEX Oncology, and CEO of Convergence Pharmaceuticals, Inc. He is currently founder and director of EmergingMed, an online clinical trial prequalification and matching database and a Director of C-PATH, an Institute focused on drug development and regulatory innovation he helped found with the FDA and the University of Arizona. Dr. Rice also held positions of Vice President of Research at Cytokine Networks (1998-1999), and Director of Cell Therapeutics (CTI) from 1993-1998. He headed a discovery laboratory at Genentech from 1987-1993. Dr. Rice is currently an inventor on over 20 patents or patent applications and has authored over 75 manuscripts and book chapters.
	Matthew Levy, M.S., M.B.A., Director, Global Market Development, Applied Biosystems Mr. Levy is the Director of Global Market Development at Applied Biosystems. He has worked closely with pharmaceutical and biotech companies over the past several years to develop solutions that improve the drug discovery and development process. In his current role, he is responsible for developing the emerging pharmaceutical market in China. As a result, he will provide a perspective on his experience to capitalize on growth opportunities within a developing economy.
	Ying Luo, Ph.D., President and CEO, Shanghai Genomics, Inc., President and COO, GNI Ltd. Dr. Luo received his Ph.D. from the University of Connecticut Health Center in 1991. After finishing postdoctoral research on HIV gene regulation at HHMI of UCSF, he joined Aviron, Clontech, and Rigel Pharmaceuticals and was responsible for vaccine development, proteomics project, and drug target discovery. In 2001, he founded Shanghai Genomics with other returnees from the USA, Europe, and Japan. The story of Shanghai Genomics was later covered in the front page of the Wall Street Journal. In 2005, Shanghai Genomics merged with GNI to become a leading Asian drug discovery company. He is currently the President and CEO of Shanghai Genomics and also the President and COO of GNI. Dr. Luo has received many rewards for his entrepreneurship and scientific achievement in China. He is also a frequent speaker at international conferences.
	Mark Engel, Chairman, Excel PharmaStudies Mr. Engle is the co-founder of Excel PharmaStudies, the largest full service clinical research organization in China with operations in Beijing, Shanghai, Guangzhou, Chengdu, Chongqing , Nanjing, and Shenyang. In the last two-plus years, Excel has been involved in about 110 phase I to IV trials in 25 cities at about 130 hospitals and covering approximately 23,000 patients. The trials have been for either local registrations or international approvals. Excel has strong medical regulatory and data management teams. Our clients include many of the top 50 international pharmaceutical companies and many of the leading Chinese pharmaceutical companies. Mr. Engle is also the co-founder of several other medically related companies in China: (1) Haoyisheng (the leading health care information, education, and software company in China); and (2) The Tiger Group of companies including Tiger Medical Products, Tiger Health Care Group, Tiger Specialty Sourcing, and TPNT.
	Carlos Genardini, CEO, Hong Kong Science and Technology Parks Corporation Mr. Genardini brings over two decades of technology management and experience to the role of CEO including four years as a Vice President and manager of Motorola’s Asia Pacific Group. During this time, Mr. Genardini became involved in developing the semiconductor and technology industries in Hong Kong and throughout the region. Mr. Genardini has set up and managed state-of-the-art chip design facilities in Hong Kong, Singapore, and China, sat on the committees of engineering departments in the University of Hong Kong and the City University of Hong Kong, and was a founding Board member of the Provisional Hong Kong Science Park Company Ltd., which later merged into the present Hong Kong Science and Technology Parks Corporation. Mr. Genardini has a track record as an experienced executive of a major multinational corporation, knowledge of global and regional technology industries, an extensive network of contacts, and commitment and enthusiasm in helping to promote and further develop the Science Park.
	Johan PE Karlberg, M.D., Ph.D., Director, Clinical Trials Centre, The University of Hong Kong Professor Karlberg has, since its establishment in 1998, been the Director of the Clinical Trials Centre (CTC), The University of Hong Kong. He has a B.Sc. in Statistics and Education (Goteborg, Sweden), a M.D. (Goteborg), and a Ph.D. in Anatomy and Cell Biology (Goteborg). He joined the Department of Pediatrics, The University of Hong Kong in 1993. Professor Karlberg’s research interests cover paediatric endocrinology, biostatistics, and clinical trials; he has his name on 200 plus publications and has been involved in supervising some 75 postgraduate students. The main focus of his current activities in the CTC is promotion of Good Clinical Practice (GCP) in the faculty, in Hong Kong, and in the region. Over the past years, CTC has established a large range of trial related services such as central laboratory services, research pharmacy services, project management, monitoring, IRB submission assistance, protocol development, data management and medical statistics. CTC has been, or is currently, involved in 262 global clinical trials.

For more information, please contact:
Micah Lieberman, Conference Director, Cambridge Healthtech Institute
E-mail: mlieberman@pharmaseries.com

For exhibit and sponsorship information, please contact:
Laura Ames, Sales Manager, at 781-972-5483 
lames@healthtech.com